MetaCap

Janux Therapeutics Inc. (JANX)

NASDAQ: JANXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

10.08-0.21 (-2.04%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

JANX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$616.73M
EPS (TTM)
-$1.59
52-week range
10.05 – 35.34
Day range
10.05 – 10.54
Volume / Avg
1.11M / 961.56K
Beta
—

52-week range

$10.05$35.34

JANX stock today

Janux Therapeutics (JANX) closed at $10.08 on Nov 20, down 2.04% (-$0.21), versus the S&P 500's 3.70% decline. Shares are 71.5% below their 52-week high of $35.34, set on Nov 26, 2025 and 0.3% above the 52-week low of $10.05, near the bottom of the past year's range. JANX is down 27.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 65.0%.

Janux Therapeutics has posted a net loss over the last twelve months (EPS of -$1.59), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Janux Therapeutics

Company profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. David Alan Campbell Ph.D.
Headquarters
San Diego, CA
Employees
114
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Janux Therapeutics generated $10.0 million in revenue, down 5.6% from fiscal 2024, its first annual decline since 2023. Janux Therapeutics reported a net loss of $113.6 million, compared with a loss of $69.0 million a year earlier. Operating margin was -1576.7%.

Janux Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$10.00M$10.59M$8.08M$8.61M$3.64M
Growth-5.55%+30.99%-6.14%+136.79%—
Net income$-113.63M$-68.99M$-58.29M$-63.06M$-32.67M
EPS (diluted)$-1.83$-1.28$-1.32$-1.52$-1.39

Analyst forecast

Forecast

Consensus (18 analysts)

strong_buy

Avg. price target

$33.14+228.77%

  • Strong buy 2
  • Buy 13
  • Hold 2
  • Sell 0
  • Strong sell 1

Target range

Low $15.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.34 vs $-0.45
Surprise
+24.44%

JANX news

All JANX news

Janux Therapeutics peers

Health Care sector
JANX peer companies
CompanyPrice% ChgMarket capCompare
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs JANX
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs JANX
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs JANX
ANNXAnnexon Inc.3.10-9.09%$591.37Mvs JANX
SGMTSagimet Biosciences Inc. Series A9.08-5.61%$648.02Mvs JANX
IMMXImmix Biopharma Inc.6.96-1.14%$583.33Mvs JANX
DSGNDesign Therapeutics Inc.9.02-3.22%$577.61Mvs JANX
NVCTNuvectis Pharma Inc.19.39-2.27%$666.80Mvs JANX

Indexes, lists and sector

Janux Therapeutics stock FAQ

What is Janux Therapeutics's stock price today?

JANX last traded at $10.08 as of Nov 20, 4:00 PM EST, down 2.04% on the day. Prices are delayed at least 15 minutes.

Who is Janux Therapeutics's CEO?

Dr. David Alan Campbell Ph.D. is the chief executive officer of Janux Therapeutics Inc., which has about 114 employees.

What is the JANX 52-week high?

The 52-week high for JANX is $35.34 and the 52-week low is $10.05. The stock is currently 71.5% below its high.

Compare JANX